Spoken Alpha
KRYS
Krystal Biotech, Inc.
Overview
Krystal Biotech, Inc is a Healthcare company operating in Biotechnology with a $10.25B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 2, 2026).
10 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0411 Q&A exchanges
- Q4 FY2025Earnings2026-02-1729 Q&A exchanges
- Q3 FY2025Earnings2025-11-0315 Q&A exchanges
- Q2 FY2025Earnings2025-08-0421 Q&A exchanges
- Q1 FY2025Earnings2025-05-0623 Q&A exchanges
- Q4 FY2024Earnings2025-02-1916 Q&A exchanges
- Q3 FY2024Earnings2024-11-0420 Q&A exchanges
- Q1 FY2024Earnings2024-05-0616 Q&A exchanges
- Q4 FY2023Earnings2024-02-2630 Q&A exchanges
- Q3 FY2023Earnings2023-11-0627 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-02EPS— vs $1.99—Rev— vs ——EODHD
- Q1 FY20262026-05-10EPS$1.83 vs $1.46+25.3%Rev$116.4M vs ——EODHD
- Q4 FY20252026-02-16EPS$1.70 vs $1.58+7.6%Rev$107.1M vs ——EODHD
- Q3 FY20252025-11-02EPS$2.66 vs $1.09+100.0%Rev$97.8M vs ——EODHD
- Q2 FY20252025-08-03EPS$1.29 vs $1.22+5.7%Rev$96.0M vs ——EODHD
- Q1 FY20252025-05-04EPS$1.20 vs $1.03+16.1%Rev$88.2M vs ——EODHD
- Q4 FY20242025-02-23EPS$1.53 vs $1.85-17.4%Rev$91.1M vs ——EODHD
- Q3 FY20242024-11-03EPS$0.91 vs $0.90+1.1%Rev$83.8M vs ——EODHD
- Q2 FY20242024-08-04EPS$0.53 vs $0.58-8.6%Rev$70.3M vs ——EODHD
- Q1 FY20242024-05-05EPS$0.03 vs $0.15-80.0%Rev$45.3M vs ——EODHD
- Q4 FY20232024-02-25EPS$0.30 vs $-0.38+100.0%Rev$42.1M vs ——EODHD
- Q3 FY20232023-11-05EPS$-0.69 vs $-0.29-100.0%Rev$8.6M vs ——EODHD
- Q2 FY20232023-08-06EPS$-1.25 vs $-0.74-68.9%Rev$0 vs ——EODHD
- Q1 FY20232023-05-07EPS$-1.76 vs $-1.44-22.2%Rev$0 vs ——EODHD
- Q4 FY20222023-02-26EPS$-1.25 vs $-1.32+5.3%Rev$0 vs ——EODHD
- Q3 FY20222022-11-06EPS$-1.17 vs $-1.22+4.1%Rev$0 vs ——EODHD
- Q2 FY20222022-08-07EPS$-1.10 vs $-1.02-7.8%Rev$0 vs ——EODHD
- Q1 FY20222022-05-08EPS$-0.99 vs $-1.05+5.7%Rev$0 vs ——EODHD
- Q4 FY20212022-02-27EPS$-0.95 vs $-0.73-30.1%Rev$0 vs ——EODHD
- Q3 FY20212021-11-07EPS$-0.70 vs $-0.74+5.4%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-02 | — | $1.99 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $1.83 | $1.46 | +25.3% | $116.4M | — | — | EODHD |
| Q4 FY2025 | 2026-02-16 | $1.70 | $1.58 | +7.6% | $107.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-02 | $2.66 | $1.09 | +100.0% | $97.8M | — | — | EODHD |
| Q2 FY2025 | 2025-08-03 | $1.29 | $1.22 | +5.7% | $96.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $1.20 | $1.03 | +16.1% | $88.2M | — | — | EODHD |
| Q4 FY2024 | 2025-02-23 | $1.53 | $1.85 | -17.4% | $91.1M | — | — | EODHD |
| Q3 FY2024 | 2024-11-03 | $0.91 | $0.90 | +1.1% | $83.8M | — | — | EODHD |
| Q2 FY2024 | 2024-08-04 | $0.53 | $0.58 | -8.6% | $70.3M | — | — | EODHD |
| Q1 FY2024 | 2024-05-05 | $0.03 | $0.15 | -80.0% | $45.3M | — | — | EODHD |
| Q4 FY2023 | 2024-02-25 | $0.30 | $-0.38 | +100.0% | $42.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-05 | $-0.69 | $-0.29 | -100.0% | $8.6M | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $-1.25 | $-0.74 | -68.9% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $-1.76 | $-1.44 | -22.2% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-02-26 | $-1.25 | $-1.32 | +5.3% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-06 | $-1.17 | $-1.22 | +4.1% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $-1.10 | $-1.02 | -7.8% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-0.99 | $-1.05 | +5.7% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.95 | $-0.73 | -30.1% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-07 | $-0.70 | $-0.74 | +5.4% | $0 | — | — | EODHD |
Source: EODHD. KRYS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks KRYS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.96 | $2.90 | +36.6% | +5.3% | +7.9% |
| Q4 FY2026 | $3.79 | $2.76 | +37.2% | +2.6% | +2.0% |
| Q3 FY2026 | $3.86 | $2.96 | +30.5% | -4.9% | -6.8% |
| Q2 FY2026 | $3.83 | $2.80 | +36.7% | -2.7% | -0.1% |
| Q1 FY2025 | $3.85 | $2.97 | +29.5% | 0.0% | +2.1% |
| Q4 FY2025 | $3.91 | $2.91 | +34.3% | -4.8% | -7.2% |
| Q3 FY2025 | $3.72 | $2.88 | +29.3% | -3.6% | -2.2% |
| Q2 FY2025 | $4.02 | $2.85 | +40.9% | -2.3% | -1.7% |
| Q1 FY2024 | $4.01 | $2.96 | +35.4% | +3.3% | +4.5% |
| Q4 FY2024 | $4.50 | $3.11 | +44.8% | +1.3% | +2.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Krish S KrishnanCEO1 yr 9 mo10 callsCurrentSample
CEO since 2024 • 4/8 beats (50%) • last guidance raise Q3 FY2026
- Suma KrishnanPresident2 yr10 callsCurrentSample
PRESIDENT since 2024 • 4/8 beats (50%) • last call held guidance Q2 FY2026
- Kathryn RomanoChief Accounting Officer1 yr 4 mo6 callsCurrentSample
OTHER_C_SUITE since 2025 • 1/4 beats (25%) • last guidance raise Q1 FY2026
- Laurent Louis Jean GouxEVP, Head of International3 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2026
- John Charles ThomasEVP, General Counsel3 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last call held guidance Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for KRYS.
$ curl https://api.spokenalpha.com/v1/companies/KRYSFAQ
Frequently asked about KRYS
Where can I find Krystal Biotech, Inc.'s (KRYS) earnings call transcripts?
Spoken Alpha indexes KRYS's earnings call transcripts at https://spokenalpha.com/companies/KRYS. Each call links to attributed speakers and parsed analyst Q&A. Krystal Biotech, Inc.'s own investor relations page is at https://clinicaltrials.gov/investors.
When was Krystal Biotech, Inc.'s most recent earnings call?
Krystal Biotech, Inc. (KRYS) held its most recent earnings call on 2026-05-04, covering fiscal Q1 2026.
What sector is KRYS in?
Krystal Biotech, Inc. (KRYS) operates in the Healthcare sector (Biotechnology industry).